[
  {
    "ticker": "MPP",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964021",
    "id": "02964021",
    "pages": 2,
    "price_sensitive": true,
    "date": "20250701",
    "time": "0731",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l9932r1ktnvl.pdf",
    "summary": "<h3><strong>Capital Raising Announcement Summary:</strong></h3>\n<ul>\n<li><strong>Structure:</strong> Renounceable rights issue ($9m) + Placement to cornerstone investor Amari Metals ($6m minimum, up to $15m total). Oversubscription facility possible (max $24m raised).  </li>\n<li><strong>Pricing:</strong> $0.03 per share.  </li>\n<li><strong>Outcome:</strong> Amari to own 51% post-capital raise.  </li>\n<li><strong>Key Dates:</strong> Shareholder meeting expected late August 2025; offer documentation sent early August 2025.  </li>\n<li><strong>New Debt Facility:</strong> 3-year loan agreed with existing syndicate member (same pricing as current facility).  </li>\n<li><strong>Conditions:</strong> Shareholder approval, final banking docs, and cross-completion required.</li>\n</ul>",
    "usage": {
      "prompt_tokens": 1159,
      "completion_tokens": 154,
      "total_tokens": 1313,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-06-30T21:48:35.590884"
  },
  {
    "ticker": "AFP",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964020",
    "id": "02964020",
    "pages": 4,
    "price_sensitive": false,
    "date": "20250701",
    "time": "0731",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l990zgn71gvv.pdf",
    "summary": "<h3><strong>AFT Pharmaceuticals \u2013 June Quarter FY26 Investor Update Summary</strong></h3>\n<ul>\n<li><strong>Combogesic IV (Maxigesic IV) launched in Canada</strong> \u2013 Sales commence as part of North American expansion strategy.  </li>\n<li><strong>Extended US licensing agreement with Hikma Pharmaceuticals</strong> \u2013 Covers both Combogesic IV and Rapid tablet, restructuring profit-sharing to direct quarterly payments.  </li>\n<li><strong>R&amp;D pipeline progress</strong>:  </li>\n<li><strong>Antibiotic eyedrop</strong>: Pre-IND filed with FDA, IND targeted by year-end.  </li>\n<li><strong>Strawberry Birthmarks topical</strong>: Pre-IND filing planned this year.  </li>\n<li><strong>Novel iron injection</strong>: IND filing expected by year-end.  </li>\n<li><strong>Paediatric Maxigesic IV study in preparation</strong> \u2013 Aims to expand approved patient population.  </li>\n<li><strong>Five out-licensing deals completed</strong> \u2013 Additional agreements under negotiation.  </li>\n</ul>\n<p><strong>No capital raising, financial figures, or material trading-sensitive dates identified.</strong></p>",
    "usage": {
      "prompt_tokens": 2426,
      "completion_tokens": 199,
      "total_tokens": 2625,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-06-30T21:49:09.176295"
  },
  {
    "ticker": "AIA",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964018",
    "id": "02964018",
    "pages": 1,
    "price_sensitive": false,
    "date": "20250701",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l98wrcx6pw71.pdf",
    "summary": "<p>Understood. Please provide the <strong>ASX announcement PDF or its text</strong>, and I will extract the <strong>strictly material information</strong> in concise bullet points, tailored to the announcement type per your guidelines.  </p>\n<p>If the document is:<br />\n- <strong>Trading Halt</strong> \u2192 Reason only.<br />\n- <strong>Capital Raising</strong> \u2192 Structure, total AUD raised, key dates.<br />\n- <strong>Quarterly (4C)</strong> \u2192 Key operational/financial highlights, closing cash balance.<br />\n- <strong>Other</strong> \u2192 2-3 critical points impacting valuation/liquidity/capital structure.  </p>\n<p>Example outputs:<br />\n<strong>Capital Raising</strong><br />\n- <strong>Structure</strong>: Placement + SPP<br />\n- <strong>Amount</strong>: A$25M (A$20M placement + A$5M SPP)<br />\n- <strong>Key dates</strong>: Ex-date 12/10, Record 14/10, Close 28/10.  </p>\n<p><strong>Quarterly (4C)</strong><br />\n- <strong>Cash balance</strong>: A$4.2M (QoQ -12%)<br />\n- <strong>Highlights</strong>: Production 15koz Au (vs 12koz pcp), all-in cost A$1,800/oz.  </p>\n<p><strong>No material information identified</strong> (if irrelevant/non-material).  </p>\n<p>Provide the document/text, and I\u2019ll distill the key details.</p>",
    "usage": {
      "prompt_tokens": 220,
      "completion_tokens": 269,
      "total_tokens": 489,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-06-30T21:48:18.533742"
  },
  {
    "ticker": "CNU",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964019",
    "id": "02964019",
    "pages": 4,
    "price_sensitive": false,
    "date": "20250701",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l98yw68lrr7b.pdf",
    "summary": "<ul>\n<li><strong>Capital Structure Change</strong>:  </li>\n<li><strong>CIP1 Equity Securities</strong>: 85,341,018 unquoted securities redeemed at NZ$1.00 each (total NZ$85.3M).  </li>\n<li><strong>CIP1 Warrants</strong>: 7,561,881 unquoted warrants cancelled (nil consideration).  </li>\n<li>\n<p><strong>Debt Securities</strong>: NZ$85.3M repaid.  </p>\n</li>\n<li>\n<p><strong>Impact</strong>:  </p>\n</li>\n<li>Reduces outstanding CIP1 Equity Securities by 18.5% (remaining: 376.7M).  </li>\n<li>Reduces outstanding CIP1 Warrants by 43.3% (remaining: 9.9M).  </li>\n<li>\n<p>No treasury stock held post-transaction.  </p>\n</li>\n<li>\n<p><strong>Reason</strong>: Mandatory redemption triggered by dividend eligibility (effective 30 June 2025).  </p>\n</li>\n</ul>\n<p><em>Note: Transaction involves unquoted securities; no direct market liquidity impact.</em></p>",
    "usage": {
      "prompt_tokens": 1792,
      "completion_tokens": 189,
      "total_tokens": 1981,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-06-30T21:48:46.155547"
  },
  {
    "ticker": "IFT",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964017",
    "id": "02964017",
    "pages": 6,
    "price_sensitive": false,
    "date": "20250701",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l98tml9jndtl.pdf",
    "summary": "<p><strong>Dividend Announcement Summary (Appendix 3A.1):</strong><br />\n- <strong>Final dividend amount (NZD):</strong> NZD 0.1325 per share (AUD 0.1229 equivalent).<br />\n- <strong>Record date:</strong> 12/6/2025 | <strong>Ex-date:</strong> 11/6/2025 | <strong>Payment date:</strong> 2/7/2025.<br />\n- <strong>DRP strike price:</strong> NZD 10.42983548 per share (2% discount applied).<br />\n- <strong>DRP election deadline:</strong> 13/6/2025 15:00 NZ time.<br />\n- <strong>Unfranked dividend (100%)</strong>, withholding tax rate: 15%.  </p>\n<p><em>Omitted: Non-material tax details, DRP eligibility boilerplate, historical references.</em></p>",
    "usage": {
      "prompt_tokens": 2314,
      "completion_tokens": 168,
      "total_tokens": 2482,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-06-30T21:48:31.456581"
  }
]